The successful use of dronabinol for failure to thrive secondary to intestinal dysmotility

INTRODUCTION: Symptoms of severe intestinal dysmotility decrease patients’ quality of life and may prevent them from sustaining adequate oral intake. Dronabinol is a synthetic cannabinoid that is labeled for use in AIDS-related anorexia and chemotherapy-associated nausea and vomiting that has additi...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Grace H., Schwaitzberg, Steven D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446691/
https://www.ncbi.nlm.nih.gov/pubmed/25974259
http://dx.doi.org/10.1016/j.ijscr.2015.04.036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446691/
https://www.ncbi.nlm.nih.gov/pubmed/25974259
http://dx.doi.org/10.1016/j.ijscr.2015.04.036

Ejemplares similares